Aktuellt
SENASTE
Vitrolife’s Q1 shows that the headwind for Genetics will likely last until mid-2024. The combined effect from insourcing (PGT-A), ERA and EmbryoMap switching will likely contribute to a considerable headwind in Q2 (ERA could improve). Our updated view is a base case valuation of SEK 220 (245), a Bull Case of SEK 365(400), and a Bear Case of SEK 95 (100).
LÄS MER
